| Study Period | 2020-2032 | CAGR | 4.2% |
| Historical Period | 2020-2022 | Forecast Period | 2024-2032 |
| Base Year | 2023 | Base Year Market Size | USD XX Billion |
| Forecast Year | 2032 | Forecast Year Market Size | USD XX Billion |
The United States tulathromycin market size has witnessed significant growth in the past and is expected to grow at a CAGR of 4.2% during the forecast period (2022–2030). In the U.S. cattle industry, BRD remains the leading cause of morbidity and mortality in feedlots, resulting in poor performance, carcass quality, and animal health losses.
Tulathromycin is an antibiotic that works by inhibiting the growth of bacteria. In veterinary medicine, it is typically administered to treat respiratory conditions in cattle and swine. Tulathromycin is covered by Zoetis' intellectual property rights (IPR), and it is marketed as Draxxin.
BRD is the most common pathology in young and adult animals, affecting 20–25% of calves annually, 10% of which experience growth retardation and up to 6% die. Swine can also have an SRD prevalence rate of around 20%, with a mortality rate of up to 20% and a risk of sequelae in up to 40% of affected animals. Beyond the effects on animal health, BRD and SRD have a significant financial impact on the farmer because of the reduction in animal growth, the expense of diagnosis and treatment, mortality, and the cost of additional work.
Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine. Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects Swines and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.
The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.
The formulation of Draxxin, which contains the active component tulathromycin, is protected by patents in the United States, Europe, Canada, Australia, and other important markets. The patent in the United States, Europe, Canada, and Australia expires in February 2021. Till 2023, the active component tulathromycin is protected in Japan. Products containing generic tulathromycin are sold in a few nations, including Colombia, Vietnam, Belarus, Russia, Poland, and Croatia. Marketing permits for products containing generic tulathromycin.
This provides the participants with a lucrative opportunity to enter the industry and take advantage of the growth opportunity, particularly in the United States and Europe. Due to the high end-user spending power and greater reliance on beef and dairy cattle, the U.S. and Europe are the two largest markets for the consumption of antibiotics for BRD and SRD. During the forecast period, we anticipate the arrival of numerous new players in the tulathromycin market in these two areas.
The United States tulathromycin market represents a sizeable portion of the global veterinary antibiotics business. The effectiveness of the broad-spectrum antibiotic tulathromycin in treating respiratory infections in animals has made it famous. It is mostly employed in veterinary medicine. Several factors, including the rising pet ownership rate, the expansion of the livestock industry, and the rising need for animal protein, fuel the market.
With a sizable population of cattle, swine, and poultry, the United States has a thriving and highly developed livestock industry. Livestock farmers are challenged with keeping their animals healthy and productive as consumer demand for meat and dairy products rises. Tulathromycin is useful for treating livestock bacterial infections and respiratory illnesses, ensuring their health and maximizing productivity.
Additionally, the rising pet ownership rate in the United States increases the demand for tulathromycin. Companion animals, like dogs and cats, are valued parts of families, and pet owners place a high priority on their health and well-being. Tulathromycin treats various infections and ailments in pets, allowing vets to give these creatures better care and a higher quality of life.
| Report Metric | Details |
|---|---|
| Segmentations | |
| By Animal Type |
|
| Company Profiles | Zoetis Zhejiang Genebest Pharmaceutical Wisdom Pharmaceutical Amicogen Biopharm Hubei Honch Pharmaceutical Livzon New North River Pharmaceutical AVF Chemical Industrial Jiangsu Lingyun Pharmaceutical |
| Geographies Covered | |
| United States | |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The United States tulathromycin market is segmented based on animals.
Based on animals, the market is segmented into cattle and swine.
Cattle dominates the market and is expected to register a CAGR of 4.6% over the forecast period. For the treatment and prevention of bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cats, tulathromycin is used. In the United States dairy industry, respiratory disease plays a significant role in weaned calf mortality, and morbidity due to BRD negatively impacts survivability and dairy performance later in life.
